Friday 23 October | |
Essentra PLC | Third Quarter Results |
Barclays PLC | Third Quarter Results |
London Stock Exchange Group PLC | Third Quarter Results |
InterContinental Hotels Group PLC | Third Quarter Results |
Airtel Africa PLC | Half Year Results |
Avation PLC | Full Year Results |
Monday 26 October | |
THG Holdings PLC | Third Quarter Results |
Tuesday 27 October | |
Bloomsbury Publishing PLC | Half Year Results |
Plus500 Ltd | Third Quarter Results |
St James's Place PLC | Third Quarter Results |
HSBC Holdings PLC | Third Quarter Results (at 0400 GMT) |
Dechra Pharmaceuticals PLC | Trading Statement |
Whitbread PLC | Half Year Results |
Shoe Zone PLC | Trading Statement |
BP PLC | Third Quarter Results |
Hunting PLC | Trading Statement |
First Derivatives PLC | Half Year Results |
Renalytix AI PLC | Full Year Results |
ContourGlobal Group PLC | Trading Statement |
Wednesday 28 October | |
John Laing Group PLC | Trading Statement |
Ibstock PLC | Trading Statement |
Gem Diamonds Ltd | Trading Statement |
Elementis PLC | Trading Statement |
International Biotechnology Trust PLC | Full Year Results |
GlaxoSmithKline PLC | Third Quarter Results (at midday) |
Next PLC | Trading Statement |
Bank of Ireland Group PLC | Trading Statement |
Omega Diagnostics Group PLC | Trading Statement |
Itaconix PLC | Half Year Results |
Thursday 29 October | |
Royal Dutch Shell PLC | Third Quarter Results |
Angle PLC | Half Year Results |
Standard Chartered PLC | Third Quarter Results (at 0415 GMT) |
WPP PLC | Trading Statement |
Helios Towers PLC | Third Quarter Results |
Smith & Nephew PLC | Trading Statement |
Lloyds Banking Group PLC | Third Quarter Results |
Travis Perkins PLC | Trading Statement |
KAZ Minerals PLC | Third Quarter Production |
BT Group PLC | Half Year Results |
International Personal Finance PLC | Trading Statement |
Indivior PLC | Third Quarter Results |
Glanbia plc | Third Quarter Results |
Foxtons Group PLC | Trading Statement |
Evraz PLC | Trading Statement |
Smith & Nephew PLC | Third Quarter Trading Statement |
Proactis Holdings PLC | Full Year Results |
Hilton Food Group PLC | Trading Statement |
Verona Pharma PLC | Third Quarter Results |
Copyright 2020 Alliance News Limited. All Rights Reserved. |
Verona Pharma shares surge after results from latest study
(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Read more